Mon, Jan 26, 2015, 6:55 AM EST - U.S. Markets open in 2 hrs 35 mins


% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • watsonhelper watsonhelper Sep 6, 2013 6:48 AM Flag



    Watch for NGN Capital. Look them up. Bier is a highly regarded player for large capital moves with NGN in the industry. AMBS, like every other bio, is at a pivotal point with a partner, financing, licensing, etc. Becton cannot got to the board or shareholders and simple pay AMBS 200m to buy Lympro (as an example), they would have to do it based on valuation and that equates to very small money. Word is that they want to buy it, not just license it. Imagine if AMBS just said that "we don't need you, we have 18 months of operating cash". AMBS has pivotal news on several fronts, still coming for any naysayers. One was supposed to drop by now and hasn't, I suspect there's only a small filing delay. Novartis would come in with sizeable cash up front to use MANF as a platform for their projects and they would hand pick which opportunities they want to go after. Platforms are easier to get speculative valuation on once they wrap arms around all of the diseases. Get PPS up, get valuation, more to come.

    I have to note that simply getting angry at my past posts around things not happening the next day, this is a hopeful person that is doing something off of a message board, please don't do that. Let this be a forum for discussion, not to buy, sell or be manipulated. I have led conclusions to 4 events on here, the 4th is ready to drop, It wasn't anything said yet. Keep in mind that dilution is evident in every bio to thrive, AMBS hasn't even touched the edge of standard dilution in a bio by now, to get a no-short clause and other provisions, like an option to force sales at .10, they are playing with their power now, not being prayed upon with others. The company just gave you all 18 months of operations sustained. The largest concerns on this board were just that and yet there's some a little hesitant. That may be the largest news you will get at the end of the day, it staves off bankruptcy, it also opens the door for AMBS to be in control. Keep that close in mind.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Optimism tempered with reason. I like that in a post.

    • you're full of it.

    • Watsonhelper: You're not as big a helper as you'd like to think you are! You said we wouldn't be hearing from you for awhile, but alas, here you are again. You said data would be posted online at the conference before we woke up in America the other day, but it wasn't. You said everything with BD was 100% done, now you're fishing other theories. You're playing some kind of game, preying on the hopes of longs here, but I think you're a big phony wearing a mask. I wouldn't be surprised if your real motive is to hype expectations so you can then short the stock. In any event, your story doesn't add up.

    • Watson, thanks for your posts. The "Longs" here greatly appreciate your insight. I come to this MB specifically to look for YOUR posts. Thanks..................AMBS

    • Could you please tell me then how they should bring Lympro to market? They cannot do it on their own! BD is by far the best option imo!

      • 1 Reply to ibiza111
      • My opinion, Lympro goes like this, validation coming up via PR within days. Final validations take place in Q1 of 14. Market analysis is complete and governmental pricing is set in Q2 of 14, hits the streets in late 14. People place buy orders before it actually is sold OTC. Marketing has already started. First money hits shareholders in late 14 or early 15. PPS jumps to probably 30-40x mcap from here based on true valuation. BD is licensing the product, first step is their validation, as stated, very soon. Next step is BD will approach AMBS with money to take a controlling interest in distro. AMBS will not let them buy it now, very foolish move with financing secured. The second the BD validation is listed, they will immediately step in with cash to secure their first rights of refusal on the deal. My estimates before were in the 30-40m range for first cash, I suspect this will be very soon, hard to say, but probably this quarter before too many people want to get their hands on it. Hope that helps.

    • A perhaps minor but(IMO) signifcant fact has been overlooked . That is, BD has allowed it's name to be used in the context of multiple PR's from AMBS. In my experience companies like BD never allow such things unless they are fully on board . To me, maybe minor but, that is evidence of a clearly drawn credible connection to potential product development. They have moved past the vapor stage.

    • Your feedback and information is always appreciated. As you know; the posters here are from different planets (not so good ones at times). One suggestion: making any future predictions...I would recommend that its best to suggest specific news or events are looming (or coming soon) versus pinpointing an exact day. Otherwise, you are doing a great job trying to keep us shareholders informed (and you have been very directionally accurate ..for the most part). Keep it coming!!!

    • To me the financing is the best for the company and shareholders alike, it's also important to note that for "naysayers", is that no one entity would pump the amount of financial backing to date if there was little to no chance of a substantial return on their investment. It's like me walking up to a Mercedes dealership to buy me a new Benz...I am unemployed I say to the salesman, but I'm job-hunting as we speak lol...

      Sentiment: Buy

0.0775-0.0011(-1.34%)Jan 23 3:55 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Infinera Corporation
NASDAQFri, Jan 23, 2015 4:00 PM EST
Five Prime Therapeutics, Inc.
NASDAQFri, Jan 23, 2015 4:00 PM EST